AbbVie Stock Crumbles On Mixed Earnings, Slashes 2022 Earnings Outlook

AbbVie stock crumbled early Friday after the biopharma giant cut its earnings outlook and came up short on sales for its first quarter.


The company reported adjusted profit of $3.16 per share on $13.54 billion in sales. On average, analysts polled by FactSet expected AbbVie (ABBV) to earn $3.14 a share on $13.66 billion in sales.

In the year-earlier period, AbbVie earnings were $2.89 per share on $13.01 billion in sales.

For the year, AbbVie cut its earnings outlook to $13.92-$14.12 per share, which includes an 8-cent hit due to research and development, as well as a milestone payment from the first quarter. AbbVie stock analysts had predicted adjusted profit of $14.16 a share on $60.23 billion in sales.

In premarket trading on today’s stock market, AbbVie stock toppled 4.4% near 149.50.

More to follow.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.


Eli Lilly Extends Its Breakout On First-Quarter Beat, Bullish News In Obesity

Sanofi Scores A Big Beat As Dupixent Snags The Spotlight, Again

IBD Digital: Unlock IBD’s Premium Stock Lists, Tools And Analysis Today

Options Trading: How To Start Using Options, How To Manage Risk

How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *